

Income Statement FY 2014

FY 2015 thru 9/30/16

WALLSTREETRESEARCH.ORG

NEW YORK, NY LOS ANGELES, CA PALM BEACH, FL



Pressure BioSciences, Inc.

Ticker: PBIO (OTCQB)

Corporate Profile

as of November 19, 2016

Pressure BioSciences, Inc. (OTCQB: PBIO) is a medical research products and technology company. PBI, based in South Easton, Massachusetts, serves academic and government laboratories, as well as biotechnology, pharmaceutical, and other life sciences companies. PBI develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. PBI has installed approximately 300 sample preparation systems in about 160 sites worldwide. PBI reported record product sales growth of 22% during the nine months ended September 30, 2016, along with a significantly improved balance sheet. The Company is poised for rapid growth with the introduction of its new and enhanced Barocycler 2320ENHANCED instrument and associated consumable products, buoyed by its expanded marketing and sales initiatives. To continue expansion, PBI intends to add staff to its domestic sales team to focus on sales and marketing. The Company also plans to increase distribution efforts in foreign markets by gaining the right to CE mark its new Barocycler instrument.

PBI announced the sale of new instrumentation of which three of the five machines were chosen to go to the cancer research project Cancer Moonshot, a project led by Vice President Joe Biden which aims to make more therapies available to more patients, while also improving the ability to prevent cancer and enhance early detection. Cancer Moonshot is a \$1 Billion dollar initiative, which has started with \$195 million in new cancer activities at the National Institutes of Health (NIH) in 2016.

PBI recently signed an exclusive, two-year co-marketing agreement with a large strategic partner named SCIEX, which offers tremendous potential for revenue growth. SCIEX is a global leader in life sciences analytical technologies and a whollyowned subsidiary of the Danaher Corporation (NYSE: DHR). In April 2016, PBI completed an intensive, one-year project that called for the redesign and build of the initial working units of the newly improved Barocycler 2320EXTREME instrument. Designed initially for protein sample preparation prior to mass spectrometry analysis, including the SCIEX SWATH-MS ("PCT-SWATH"), the new PCT-based instrument can also be used in front of non-SCIEX mass specs, and in front of other instruments used for protein, DNA/RNA analysis. PBI has recently come to an arrangement with a local ISO-certified contract manufacturer, and has given the manufacturer an initial order for 25 Barocycler 2320EXT units. The manufacture of the initial five, commercial-grade units was completed in June 2016, and were sold immediately thereafter to key laboratories globally. The Company produced and sold four units in Q3 and plans to produce six more in Q4.

The PBI technology platform is based on constant (i.e., static) and alternating (i.e., Pressure Cycling Technology, or PCT) hydrostatic pressure; if used properly, pressure can help control the actions of molecules in biological samples, which can then have significant positive effects on scientific research studies. The Company offers products such as Barocycler Instruments, the Shredder System, and associated Consumables (PULSE, MicroPestles, and Micro Tubes). PBI holds 14 US and 10 foreign patents covering applications of PCT that offer significant advantages over competitive methods used to prepare samples for research evaluation.

PBI's market consists of an estimated 500,000 scientists in over 80,000 research laboratories worldwide. PBI focuses on biomarker/drug discovery and design, as well as forensics. Today the Company has approximately 150 worldwide customers that could be expanded to areas such as: bio-therapeutics characterization, soil & plant biology, vaccine development, counter- bioterror applications and DNA studies. With these potential target areas, the growth potential for PBI is vast

The Company continues to meet or exceed its publicly-disclosed goals, and continues to give guidance that it anticipates an up-listing to a major exchange within the next year. We believe PBIO can soon surpass its 52-week high in share price as it

FY 2015

9/30/16

Cash Flow Statement FY 2014

thru 9/30/16

continues to gain momentum. Indeed we believe that the current share price is significantly undervalued. FY 2014

Balance Sheet

	Revenue	1,374,744	1,797,691	1,556,776	Cash & cash equivalents	473,948	116,783	41,939	Operating Cash Flow	(3,210,578)	(3,819,746)	(2,737,516)	
	Gross Profit	697,712	800,937	707,789	Total Assets	1,744,132	1,804,388	1,894,601	Investing Cash Flow	(7,139)	(9,412)	(3,273)	
	Operating Loss	(3,338,350)	(3,565,182)	(2,558,448)	Total Liabilities	3,803,863	9,782,036	14,654,414	Financing Cash Flow	3,660,248	3,471,993	2,665,945	
	Net Loss	(4,612,540)	(7,415,298)	(5,933,768)	Total Shareholder's Equity	(2,059,731)	(7,977,648)	(12,759,813)	Cash at end of period	473,948	116,783	41,939	
Figure 1: PBIO 1 Year Price Chart		0.65	PBIO Daily -	Figur	e 2: PBIO 2 Yea	ar Price C	Chart	11×16×16 0,60					
						0.60				. Nr. i		0.50	
			Phan in			0.55				AL/ULA	condition to	0.45	
		11,11	ma ^r had	A	and the Lea	0.45				11.46.3414	AND PROPERTY.	0.40	
			and a silvery	and the state of t	Warding to the tree	0.40		la. Mata		//	(1) 191	0.35	
	Philippine.	A Park		a blat and	The Total	0.35	nakt 7 V	MAY THAT THE	Mark A Company			0.20	
	16,14,16,919	of Liebba			P District P	0.30	The second second	hul 4	"Ultra Philips, A.			0.25	

Sector: Healthcare

Industry: Medical Devices & **Technology**

Website: www.pressurebiosciences.com

Key Statistics

•	Price	11/18/2016	0.30	
	52 We	0.58		
	52 We	0.23		
	Avg. V	54,585		
	Beta	1.34		
	Marke	9.14M		
	Price/S	4.65		
	Inside	10%		
	Shares	30.87		
	Float (M)	27.01	
	EPS(91	n) Source: Yahoo Finance	-0.23	

Recent 2016 Highlights

- November 15, PBI announced 22% product revenue growth for the first 9 months, including record instrument and consumable sales. In addition, the Company has introduced a new highly-enabling instrument, which has been selected for use in the Cancer Moonshot Initiative.
- November 14, PBI announced initial close of \$610,000 in a \$2.5 Million private placement. The Company issued 1,525,000 shares of restricted common stock at \$.40 per share and common stock purchase warrants exercisable at \$.50 cents per share.
- July 28, 2016, PBI and SCIEX together have improved complex sample processing for higher quality results, reproducibility and depth of proteomic analysis. The firms are working to standardize the protocol for complex samples and thus far achieved capabilities of processing up to 16 samples in six hours, much faster than current methods.
- March 31, 2016, PBI closed an additional \$769K in PIPE financing. This final close brought the total working capital raised to over \$6.3M, substantially above Company's goal of \$5M. Proceeds were used to pay off all of its variable rate (floorless) convertible debt, eliminating the risks of substantial dilution. The new shares were issued at a conversion rate of \$.28 per share.

Corporate Contact Information

Pressure BioSciences Inc. Richard T. Schumacher, CEO 14 Norfolk Ave. South Easton MA, 02375 Phone: 508-230-1828 www.pressurebiosciences.com

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of \$3500 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.